Posted by ABMN Staff on Apr 25th, 2024
HSBC upgraded shares of Gilead Sciences (NASDAQ:GILD – Free Report) from a reduce rating to a hold rating in a research note issued to investors on Wednesday, Marketbeat reports. HSBC currently has $69.00 target price on the...
More of this article »